Kassouf Wassim, Agarwal Piyush K, Grossman H Barton, Leibovici Dan, Munsell Mark F, Siefker-Radtke Arlene, Pisters Louis L, Swanson David A, Dinney Colin P N, Kamat Ashish M
Division of Urology, McGill University Health Center, Montreal, Ontario, Canada.
Urology. 2009 Jan;73(1):147-52. doi: 10.1016/j.urology.2008.07.035. Epub 2008 Oct 9.
Persistent nodal disease in the surgical specimen (pN+) after preoperative chemotherapy for urothelial carcinoma is associated with a poor prognosis. To improve our understanding regarding the outcomes of such patients, we performed a retrospective review of our experience.
From 1993 to 2003, 857 patients underwent radical cystectomy for urothelial carcinoma of the bladder, and 150 were found to have pN+ disease. Of these 150 patients, 37 had pN+ disease despite preoperative chemotherapy and formed the basis of this report. The survival data were analyzed using the Kaplan-Meier method and Cox regression analysis.
The median patient age was 66 years (range 39-85), and the median follow-up was 50 months (range 13.0-58.7). The clinical stage at the initiation of preoperative chemotherapy was cT2 with lymphovascular invasion in 7, cT3b in 6, cT4a in 4, cT4b in 2, and cN+ in 18. The 2-year overall, disease-specific, and recurrence-free survival rate was 20%, 29.2%, and 13.5%, respectively. Of the 37 patients, 11 (30%) received adjuvant chemotherapy after surgery, most (73%) were platinum-based regimens. On Kaplan-Meier analysis, adjuvant chemotherapy was associated with improved recurrence-free and disease-specific survival. On multivariate analysis, surgical margin status, sex, and histologic type were significantly associated with overall survival, and the histologic type and use of adjuvant chemotherapy were significantly associated with recurrence-free survival.
Patients with persistent nodal disease despite preoperative chemotherapy have a poor prognosis. A cohort of such patients might do well with adjuvant chemotherapy. The lymph node density and pT category were not prognostic in patients with nodal metastasis after preoperative chemotherapy.
尿路上皮癌术前化疗后手术标本中存在持续性淋巴结疾病(pN+)与预后不良相关。为了更好地了解此类患者的预后情况,我们对自身经验进行了回顾性分析。
1993年至2003年,857例患者因膀胱尿路上皮癌接受了根治性膀胱切除术,其中150例被发现存在pN+疾病。在这150例患者中,37例尽管接受了术前化疗仍存在pN+疾病,构成了本报告的基础。采用Kaplan-Meier法和Cox回归分析对生存数据进行分析。
患者中位年龄为66岁(范围39 - 85岁),中位随访时间为50个月(范围13.0 - 58.7个月)。术前化疗开始时的临床分期为cT2伴淋巴管浸润7例,cT3b 6例,cT4a 4例,cT4b 2例,cN+ 18例。2年总生存率、疾病特异性生存率和无复发生存率分别为20%、29.2%和13.5%。37例患者中,11例(30%)术后接受了辅助化疗,大多数(73%)为铂类方案。根据Kaplan-Meier分析,辅助化疗与无复发生存率和疾病特异性生存率的提高相关。多因素分析显示,手术切缘状态、性别和组织学类型与总生存率显著相关,组织学类型和辅助化疗的使用与无复发生存率显著相关。
尽管术前进行了化疗,但仍存在持续性淋巴结疾病的患者预后较差。此类患者群体可能从辅助化疗中获益。术前化疗后发生淋巴结转移的患者,淋巴结密度和pT类别不具有预后价值。